Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 1,730 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 1,730 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $29.96, for a total transaction of $51,830.80. Following the completion of the sale, the chief financial officer now owns 86,370 shares in the company, valued at approximately $2,587,645.20. This trade represents a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Wednesday, January 22nd, Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total transaction of $93,967.84.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $62,279.00.

Apellis Pharmaceuticals Trading Up 1.2 %

Shares of APLS stock opened at $30.76 on Friday. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90. The company has a market cap of $3.83 billion, a PE ratio of -15.15 and a beta of 0.94. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The business’s 50 day moving average is $31.95 and its two-hundred day moving average is $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.17) earnings per share. Equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Morgan Stanley started coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target on the stock. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada restated a “sector perform” rating and issued a $26.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday. Piper Sandler decreased their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Finally, Citigroup decreased their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. KBC Group NV grew its holdings in Apellis Pharmaceuticals by 3,862.3% in the 4th quarter. KBC Group NV now owns 104,287 shares of the company’s stock valued at $3,328,000 after buying an additional 101,655 shares during the last quarter. Merit Financial Group LLC acquired a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth approximately $254,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of Apellis Pharmaceuticals by 135.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock valued at $949,000 after acquiring an additional 17,115 shares during the period. Eastern Bank grew its stake in shares of Apellis Pharmaceuticals by 87.0% in the fourth quarter. Eastern Bank now owns 21,500 shares of the company’s stock worth $686,000 after acquiring an additional 10,000 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after acquiring an additional 735,160 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).